Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2022-08-10 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于公开发行可转换公司债券摊薄即期回报的影响及填补措施的公告.doc
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company regarding the public issuance of convertible bonds and its impact on immediate diluted returns, including financial assumptions, risk disclosures, project investment plans, and commitments from the board and controlling shareholders. It discusses the financial impact of the convertible bond issuance on earnings per share and other financial metrics, but it is not a full financial report like an annual or interim report. It is a regulatory disclosure focused on capital raising and its effects, including detailed project descriptions and risk factors. The document is lengthy (over 12,000 characters) and contains substantive financial and operational information related to a financing event. This fits the category of a Capital/Financing Update (CAP) rather than an Annual Report (10-K), Earnings Release (ER), or Regulatory Filing (RNS).
2022-08-10 Chinese
益丰药房公开发行可转换公司债券募集资金使用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed feasibility analysis report for the use of funds raised through a public issuance of convertible corporate bonds by 益丰大药房连锁股份有限公司. It includes comprehensive descriptions of investment plans, project overviews, necessity and feasibility analyses, investment budgets, implementation details, and the impact on the company's operations and financial status. The content focuses on capital raising and the intended use of the raised funds, which aligns with updates on company fundraising and capital structure changes. It is not a financial report like an annual or interim report, nor is it a regulatory announcement or certification. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2022-08-10 Chinese
益丰药房募集资金使用管理制度.
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金使用管理制度" which translates to "Fundraising Capital Usage Management System" for a company. It details the rules, principles, and procedures for managing and using funds raised through securities issuance, including storage, usage, supervision, and reporting requirements. The content is regulatory and procedural in nature, focusing on the management of capital raised by the company rather than reporting financial results or announcing specific events. It does not contain financial statements, earnings data, or meeting results. It is a detailed internal policy document related to capital management and fundraising compliance. This fits best under the category of Capital/Financing Update (CAP), as it relates to the management and use of capital raised by the company, rather than an announcement or a report publication. The document length is sufficient and contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2022-08-10 Chinese
益丰药房关于最近五年未被证券监管部门和交易所采取监管措施或处罚的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (650 characters) from the board of directors of 益丰大药房连锁股份有限公司 stating that in the past five years, the company has not been subject to any regulatory measures or penalties by securities regulatory authorities or stock exchanges. It references a board meeting and a self-inspection result but does not contain any financial data or detailed report content. The document is an official regulatory announcement about compliance status rather than a full report or financial statement. Given its brevity and content, it fits best under Regulatory Filings (RNS) as a general compliance announcement.
2022-08-10 Chinese
湖南启元律师事务所关于益丰大药房连锁股份有限公司2022年第二次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legitimacy and procedures of a company's 2022 second extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or financial performance data but focuses on the legal validation of the shareholders' meeting process and results. It is not an announcement of voting results per se, but a legal opinion on the meeting's legality. This type of document fits best under Regulatory Filings (RNS) as it is a legal compliance document related to corporate governance and shareholder meetings, not a direct report of voting results or management changes.
2022-08-04 Chinese
益丰药房2022年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the company's 2022 second extraordinary general meeting of shareholders. It includes details about the meeting date, location, attendance, voting results on specific proposals, and legal witness statements. The content focuses on the official voting results and procedural compliance rather than the meeting materials or presentations themselves. The document length is short (1539 characters) and it is clearly an announcement of voting results from a shareholder meeting, not a full report or presentation. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-08-04 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.